You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 7, 2024

CLINICAL TRIALS PROFILE FOR PRINIVIL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for PRINIVIL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00459056 ↗ The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients Completed GlaxoSmithKline Phase 3 2007-04-01 The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health.
NCT00459056 ↗ The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients Completed St. Paul Heart Clinic Phase 3 2007-04-01 The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health.
NCT00605072 ↗ The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial Completed Hebrew SeniorLife Phase 2 2008-01-01 The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.
NCT00605072 ↗ The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial Completed National Institute on Aging (NIA) Phase 2 2008-01-01 The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.
NCT00605072 ↗ The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial Completed University of Southern California Phase 2 2008-01-01 The purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. The hypothesis is that treatment with an angiotensin receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACEI) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (HCTZ), independent of blood pressure level.
NCT01234922 ↗ Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors Terminated Comprehensive Cancer Center of Wake Forest University Phase 2 2011-02-01 RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure. PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.
NCT01234922 ↗ Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors Terminated Wake Forest University Health Sciences Phase 2 2011-02-01 RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure. PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril, ramipril, or losartan potassium works in treating hypertension in patients with solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PRINIVIL

Condition Name

Condition Name for PRINIVIL
Intervention Trials
Hypertension 7
Hypertension, Resistant to Conventional Therapy 1
Hypotension on Induction 1
Abdominal Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PRINIVIL
Intervention Trials
Hypertension 5
Osteonecrosis 1
Cognition Disorders 1
Lung Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PRINIVIL

Trials by Country

Trials by Country for PRINIVIL
Location Trials
United States 18
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PRINIVIL
Location Trials
California 4
Minnesota 4
Nebraska 2
North Carolina 2
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PRINIVIL

Clinical Trial Phase

Clinical Trial Phase for PRINIVIL
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PRINIVIL
Clinical Trial Phase Trials
Completed 7
Recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PRINIVIL

Sponsor Name

Sponsor Name for PRINIVIL
Sponsor Trials
National Cancer Institute (NCI) 3
Mayo Clinic 2
GlaxoSmithKline 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PRINIVIL
Sponsor Trials
Other 13
NIH 6
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.